Pancreatic Cancer Research

ResearcherRoyal Surrey County HospitalActive in the last 2 years

Gary Middleton

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5695-3474; OpenAlex author ID A5037541807. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 9

  1. Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. Co-author DOI 10.1200/jco.24.01118↗
  2. Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade. Co-author DOI 10.1158/2326-6066.cir-22-0121↗
  3. Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma. Co-author DOI 10.7554/elife.86125↗
  4. NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype. Co-author DOI 10.1080/2162402x.2020.1845424↗
  5. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. Co-author DOI 10.1001/jamasurg.2019.3337↗
  6. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-lab… Co-author DOI 10.1016/s0140-6736(16)32409-6↗
  7. Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2015.468↗
  8. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patie… Last author DOI 10.1007/s00262-013-1502-y↗
  9. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an … Co-author DOI 10.1016/s1470-2045(14)70236-0↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Francesca Marcon · 3 shared papers, 2020–2023 · strength 0.41
  2. Sandra Margielewska‐Davies · 3 shared papers, 2020–2023 · strength 0.41
  3. Paul A. H. Moss · 3 shared papers, 2020–2023 · strength 0.41
  4. Hayden Pearce · 3 shared papers, 2020–2023 · strength 0.41
  5. Keith John Roberts · 3 shared papers, 2020–2023 · strength 0.41
  6. John P. Neoptolemos · 6 shared papers, 2014–2025 · strength 0.40
  7. David Cunningham · 5 shared papers, 2014–2025 · strength 0.34
  8. Juan W. Valle · 5 shared papers, 2014–2025 · strength 0.34
  9. Paula Ghaneh · 4 shared papers, 2016–2025 · strength 0.33
  10. Daniel H. Palmer · 4 shared papers, 2016–2025 · strength 0.33
  11. Wayne D. Croft · 2 shared papers, 2023 · strength 0.30
  12. Sarah F. Powell-Brett · 2 shared papers, 2023 · strength 0.30
  13. Paul J. Ross · 4 shared papers, 2014–2025 · strength 0.30
  14. Olusola Olusesan Faluyi · 3 shared papers, 2017–2025 · strength 0.27
  15. Yuk Ting Ma · 3 shared papers, 2017–2025 · strength 0.27
  16. Bengt L. G. Glimelius · 3 shared papers, 2017–2025 · strength 0.27
  17. Thilo Hackert · 3 shared papers, 2017–2025 · strength 0.27
  18. Tim Meyer · 3 shared papers, 2017–2025 · strength 0.27
  19. Pascal R. Hammel · 3 shared papers, 2017–2025 · strength 0.27
  20. Harpreet Singh Wasan · 3 shared papers, 2017–2025 · strength 0.27
  21. Christopher Michael Halloran · 3 shared papers, 2017–2025 · strength 0.27
  22. Peter J. Bailey · 1 shared paper, 2025 · strength 0.17
  23. Christoph Springfeld · 1 shared paper, 2025 · strength 0.17
  24. Christoph W. Michalski · 1 shared paper, 2025 · strength 0.17
  25. Alan Anthoney · 3 shared papers, 2014–2019 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.